Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 2/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23030401 | 0.95 | BDKRB2 (0.41) | BDKRB2ALDH1A1HTTSMN1; SMN2RIPK1 | |
| SCHEMBL13003497 | 0.83 | S1PR1 (0.37) | BDKRB2LMNAHTR2AHTTRARB | |
| SCHEMBL23030534 | 0.81 | HTT (0.35) | ALDH1A1HTTRIPK1 | |
| SCHEMBL17825557 | 0.77 | LIPG (0.36) | BDKRB2LMNAALDH1A1RARBRARA | |
| SCHEMBL28167914 | 0.76 | RARB (0.53) | ALDH1A1RARBRARARARG | |
| SCHEMBL14353644 | 0.76 | BDKRB2 (0.56) | BDKRB2LMNAHTR2A | |
| SCHEMBL28163233 | 0.76 | BDKRB2 (0.56) | BDKRB2LMNAHTR2A | |
| SCHEMBL14402388 | 0.76 | HTR2A (0.53) | LMNAHTR2AALDH1A1RARBRARA | |
| SCHEMBL8036329 | 0.76 | BDKRB2 (0.37) | BDKRB2LMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL14353201 | 0.76 | BDKRB2 (0.37) | BDKRB2LMNAHTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | NEKTAR THERAPEUTICS (US) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322107-B2 | N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor | OPRK1, OPRM1, OPRD1 | BDKRB2 382/4885LMNA 4388/4885HTR2A 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.